{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T05:28:36Z","timestamp":1772256516019,"version":"3.50.1"},"reference-count":36,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IRDR"],"published-print":{"date-parts":[[2026,2,25]]},"DOI":"10.5582\/irdr.2025.01065","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T22:09:36Z","timestamp":1770329376000},"page":"95-105","source":"Crossref","is-referenced-by-count":0,"title":["Comparative analysis of adverse event reporting signals between Satralizumab and Inebilizumab in neuromyelitis optica spectrum disorder: A pharmacovigilance study using the FDA Adverse Event Reporting System"],"prefix":"10.5582","volume":"15","author":[{"given":"Yuanyuan","family":"Zhao","sequence":"first","affiliation":[{"name":"Hebei Key Laboratory of Neuroimmunological Regulation and Mental Health, The First Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Neuroimmunological Regulation and Mental Health, The First Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Neuroimmunological Regulation and Mental Health, The First Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunhua","family":"Zhou","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Neuroimmunological Regulation and Mental Health, The First Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yupei","family":"Hao","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Neuroimmunological Regulation and Mental Health, The First Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Neuroimmunological Regulation and Mental Health, The First Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Neuroimmunological Regulation and Mental Health, The First Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuying","family":"Li","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Neuroimmunological Regulation and Mental Health, The First Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zengren","family":"Zhao","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Neuroimmunological Regulation and Mental Health, The First Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Huda S, Whittam D, Bhojak M, Chamberlain J, Noonan C, Jacob A. Neuromyelitis optica spectrum disorders. Clin Med (Lond). 2019; 19:169-176.","DOI":"10.7861\/clinmedicine.19-2-169"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Yata T, Sato G, Ogawa K, <i>et al<\/i>. Contribution of germline and somatic mutations to risk of neuromyelitis optica spectrum disorder. Cell Genom. 2025; 5:100776.","DOI":"10.1016\/j.xgen.2025.100776"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hor JY, Asgari N, Nakashima I, <i>et al<\/i>. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol. 2020; 11:501.","DOI":"10.3389\/fneur.2020.00501"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Valencia-Sanchez C, Wingerchuk DM. Emerging targeted therapies for neuromyelitis optica spectrum disorders. BioDrugs. 2021; 35:7-17.","DOI":"10.1007\/s40259-020-00460-9"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Yong HYF, Burton JM. A clinical approach to existing and emerging therapeutics in neuromyelitis optica spectrum disorder. Curr Neurol Neurosci Rep. 2023; 23:489-506.","DOI":"10.1007\/s11910-023-01287-x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Heo YA. Satralizumab: First approval. Drugs. 2020; 80:1477-1482.","DOI":"10.1007\/s40265-020-01380-2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Chen D, Gallagher S, Monson NL, Herbst R, Wang Y. Inebilizumab, a B cell-depleting anti-CD19 antibody for the treatment of autoimmune neurological diseases: Insights from preclinical studies. J Clin Med. 2016; 5:107.","DOI":"10.3390\/jcm5120107"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Frampton JE. Inebilizumab: First approval. Drugs. 2020; 80:1259-1264.","DOI":"10.1007\/s40265-020-01370-4"},{"key":"9","unstructured":"9. Delphi Expert Panel for the Appropriate Use of Inebilizumab. Expert recommendations for the appropriate use of Inebilizumab in neuromyelitis optica spectrum disorder (2024). Chinese Journal of Clinical Neurosciences. 2025; 33:241-253. (in Chinese)"},{"key":"10","unstructured":"10. Jiang Q, Jiang G, Zhu Q, Zhao S. Comprehensive evaluation of drug selection for sequential treatment of neuromyelitis optica spectrum disorders with monoclonal antibodies. Chinese Journal of Modern Applied Pharmacy. 2025; 42:2706-2713. (in Chinese)"},{"key":"11","unstructured":"11. Neuro-ophthalmology Group of Ophthalmology Branch of Chinese Medical Association; Evidence-based Medicine Center of Lanzhou University\/World Health Organization Collaborating Centre for Guideline Implementation and Knowledge Translation. Evidence-based guidelines for diagnosis and treatment of demyelinating optic neuritis in China (2021). Zhonghua Yan Ke Za Zhi. 2021; 57:171-186. (in Chinese)"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Yamamura T, Isobe N, Kawachi I, Nohara C, Miyazaki Y, Tomita M, Tsumuraya T, Yamashita K, Nakahara J, Nakashima I, Fujihara K. Safety and effectiveness of Satralizumab in Japanese patients with neuromyelitis optica spectrum disorder: A 6-month interim analysis of post-marketing surveillance. Neurol Ther. 2024; 13:1361-1383.","DOI":"10.1007\/s40120-024-00640-7"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Cree BAC, Kim HJ, Weinshenker BG, <i>et al<\/i>. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: End-of-study results from the open-label period of the N-MOmentum trial. Lancet Neurol. 2024; 23:588-602.","DOI":"10.1016\/S1474-4422(24)00077-2"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Bennett JL, Fujihara K, Saiz A, <i>et al<\/i>. Long-term efficacy and safety of Satralizumab in patients with neuromyelitis optica spectrum disorder from the SAkuraMoon Open-Label Extension Study. Neurol Neuroimmunol Neuroinflamm. 2025; 12:e200450.","DOI":"10.1212\/NXI.0000000000200494"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Chen X, Wang J, Chen C, Wang J, Du L, Qin W, Xu Z, Liu L, Qin X, Kong F. Abrupt breathlessness: Pneumocystis jirovecii pneumonia associated with Inebilizumab in neuromyelitis optica spectrum disorder: A case report and literature review. Infect Drug Resist. 2025; 18:4109-4118.","DOI":"10.2147\/IDR.S534677"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Liu H, Yang Q, Li Z, Yan S, Ming S. Systematic analysis of sugammadex-related adverse drug reaction signals using FAERS database. Int J Surg. 2025; 111:1988-1994.","DOI":"10.1097\/JS9.0000000000002194"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Jiang Y, Zhou L, Shen Y, Zhou Q, Ji Y, Zhu H. Safety assessment of Brexpiprazole: Real-world adverse event analysis from the FAERS database. J Affect Disord. 2024; 346:223-229.","DOI":"10.1016\/j.jad.2023.11.025"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004; 13:519-523.","DOI":"10.1002\/pds.1001"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001; 10:483-486.","DOI":"10.1002\/pds.677"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998; 54:315-321.","DOI":"10.1007\/s002280050466"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Jiang Y, Du Z, Shen Y, Zhou Q, Zhu H. The correlation of Esketamine with specific adverse events: A deep dive into the FAERS database. Eur Arch Psychiatry Clin Neurosci. 2025; 275:1373-1381.","DOI":"10.1007\/s00406-023-01732-5"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Bagherieh S, Afshari-Safavi A, Vaheb S, Kiani M, Ghaffary EM, Barzegar M, Shaygannejad V, Zabeti A, Mirmosayyeb O. Worldwide prevalence of neuromyelitis optica spectrum disorder (NMOSD) and neuromyelitis optica (NMO): A systematic review and meta-analysis. Neurol Sci. 2023; 44:1905-1915.","DOI":"10.1007\/s10072-023-06617-y"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Nakashima I, Nakahara J, Yasunaga H, Yamashita M, Nishijima N, Satomura A, Nio M, Fujihara K. Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims database. Mult Scler Relat Disord. 2024; 84:105502.","DOI":"10.1016\/j.msard.2024.105502"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. K\u00fcmpfel T, Giglhuber K, Aktas O, <i>et al<\/i>. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. J Neurol. 2024; 271:141-176.","DOI":"10.1007\/s00415-023-11910-z"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Takahashi Y, Kezuka T, Shikishima K, Yamagami A, Chuman H, Nakamura M, Ueki S, Kimura A, Hashimoto M, Tatsui S, Mashimo K, Ishikawa H. Usage status of biologics for the chronic treatment of optic neuritis in neuromyelitis optica spectrum disorders in Japan. Jpn J Ophthalmol. 2025; 69:81-92.","DOI":"10.1007\/s10384-024-01129-4"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Giglhuber K, Berthele A. Adverse events in NMOSD therapy. Int J Mol Sci. 2022; 23:4154.","DOI":"10.3390\/ijms23084154"},{"key":"27","unstructured":"27. Food and Drug Administration, US UPLIZNA Product Information. <i>https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761142s000lbl.pdf<\/i> (accessed October 1, 2025)."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Asseyer S, Cooper G, Paul F. Pain in NMOSD and MOGAD: A systematic literature review of pathophysiology, symptoms, and current treatment strategies. Front Neurol. 2020; 11:778.","DOI":"10.3389\/fneur.2020.00778"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Ikeguchi R, Shimizu Y, Kuroda R, Todo K. Satralizumab treatment in neuromyelitis optica spectrum disorder: Effects on relapse, pain, and other medications used: a retrospective chart review. Mult Scler Relat Disord. 2025; 103:106706.","DOI":"10.1016\/j.msard.2025.106706"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Ringelstein M, Ayzenberg I, Harmel J, <i>et al<\/i>. Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. JAMA Neurol. 2015 Jul; 72(7):756-63.","DOI":"10.1001\/jamaneurol.2015.0533"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Paul F, Marignier R, Palace J, <i>et al.<\/i> International delphi consensus on the management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab. Neurol Neuroimmunol Neuroinflamm. 2023; 10:e200124.","DOI":"10.1212\/NXI.0000000000200124"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Brod SA. Immune reconstitution therapy in NMOSD. Mult Scler Relat Disord. 2021; 52:102971.","DOI":"10.1016\/j.msard.2021.102971"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Siriratnam P, Huda S, Van Der Walt A, <i>et al<\/i>. Prevalence of progression independent of relapse activity and relapse-associated worsening in patients with AQP4-IgG-Positive NMOSD. Neurology. 2024; 103:e209940.","DOI":"10.1212\/WNL.0000000000209940"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Yin Z, Qiu Y, Duan A, Fang T, Chen Z, Wu J, Wang Z, Chen G. Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: A Bayesian network meta-analysis.J Neurol. 2023; 270:2950-2963.","DOI":"10.1007\/s00415-023-11641-1"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Abboud H, Zheng C, Kar I, Chen CK, Sau C, Serra A. Current and emerging therapeutics for neuromyelitis optica spectrum disorder: Relevance to the COVID-19 pandemic. Mult Scler Relat Disord. 2020; 44:102249.","DOI":"10.1016\/j.msard.2020.102249"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Holian AH, Weinshenker BG. Emerging role of targeted monoclonal antibodies in neuromyelitis optica spectrum disorders. BioDrugs. 2025; 39:573-589.","DOI":"10.1007\/s40259-025-00729-x"}],"container-title":["Intractable &amp; Rare Diseases Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/15\/1\/15_2025.01065\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:04:41Z","timestamp":1772251481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/15\/1\/15_2025.01065\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5582\/irdr.2025.01065","relation":{},"ISSN":["2186-361X","2186-3644"],"issn-type":[{"value":"2186-361X","type":"electronic"},{"value":"2186-3644","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"article-number":"2025.01065"}}